Mika Kontro

10PUBLICATIONS
91CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyMolecular targetsPredictive and prognostic markersCharacterisation of biological macromolecules
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (10)

|Aug 14, 2026
TIM3 blockade with hypomethylating therapy restores NK-cell and cytotoxic CD4+ T-cell activity in patients with AML or MDS.

|Jan 14, 2026
Drivers of clinical resistance to venetoclax and hypomethylating agents in acute myeloid leukemia and strategies for improving efficacy.

Ida Vänttinen, Joseph Saad, Tanja Ruokoranta

|May 12, 2025
A Machine Learning-Based Strategy Predicts Selective and Synergistic Drug Combinations for Relapsed Acute Myeloid Leukemia.

Yingjia Chen, Liye He, Aleksandr Ianevski

|Oct 02, 2024
Ex vivo venetoclax sensitivity predicts clinical response in acute myeloid leukemia in the prospective VenEx trial.

Sari Kytölä, Ida Vänttinen, Tanja Ruokoranta

|Apr 01, 2024
Targeting CD33+ Acute Myeloid Leukemia with GLK-33, a Lintuzumab-Auristatin Conjugate with a Wide Therapeutic Window.

Tero Satomaa, Henna Pynnönen, Olli Aitio

|Jan 10, 2024
Monosomy 7/del(7q) cause sensitivity to inhibitors of nicotinamide phosphoribosyltransferase in acute myeloid leukemia.

Samuli Eldfors, Joseph Saad, Nemo Ikonen

Pageof 2

Frequent Collaborators

8 joint publications

Caroline Heckman

6 joint publications

Kimmo Porkka

5 joint publications

Heikki Kuusanmäki

4 joint publications

Joseph Saad